Deltec Asset Management LLC Takes $1.44 Million Position in Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Deltec Asset Management LLC purchased a new position in Poseida Therapeutics, Inc. (NASDAQ:PSTX) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 150,000 shares of the company’s stock, valued at approximately $1,440,000. Deltec Asset Management LLC owned approximately 0.15% of Poseida Therapeutics at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of PSTX. Dimensional Fund Advisors LP increased its stake in shares of Poseida Therapeutics by 1.6% during the second quarter. Dimensional Fund Advisors LP now owns 599,812 shares of the company’s stock valued at $1,749,000 after purchasing an additional 9,672 shares in the last quarter. Marshall Wace LLP bought a new position in Poseida Therapeutics during the 2nd quarter valued at approximately $31,000. Squarepoint Ops LLC purchased a new position in Poseida Therapeutics during the second quarter valued at $241,000. AQR Capital Management LLC boosted its holdings in Poseida Therapeutics by 376.5% in the second quarter. AQR Capital Management LLC now owns 51,741 shares of the company’s stock worth $151,000 after acquiring an additional 40,882 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in shares of Poseida Therapeutics by 14.2% in the second quarter. The Manufacturers Life Insurance Company now owns 28,520 shares of the company’s stock worth $83,000 after acquiring an additional 3,552 shares during the last quarter. 46.87% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on PSTX. Piper Sandler cut shares of Poseida Therapeutics from an “overweight” rating to a “neutral” rating and set a $10.00 price target on the stock. in a research note on Monday, December 2nd. Cantor Fitzgerald downgraded shares of Poseida Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 26th. William Blair reissued a “market perform” rating on shares of Poseida Therapeutics in a research report on Tuesday, November 26th. HC Wainwright reiterated a “neutral” rating and set a $9.00 target price (down from $20.00) on shares of Poseida Therapeutics in a research note on Tuesday, November 26th. Finally, BTIG Research reissued a “neutral” rating on shares of Poseida Therapeutics in a report on Tuesday, November 26th. Five research analysts have rated the stock with a hold rating, According to MarketBeat, Poseida Therapeutics currently has an average rating of “Hold” and an average target price of $9.50.

Insider Activity at Poseida Therapeutics

In other news, Chairman Mark J. Gergen sold 30,000 shares of the company’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $9.46, for a total value of $283,800.00. Following the completion of the sale, the chairman now directly owns 651,291 shares in the company, valued at $6,161,212.86. This represents a 4.40 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 2.90% of the stock is owned by company insiders.

Poseida Therapeutics Price Performance

PSTX opened at $9.50 on Wednesday. The stock has a market capitalization of $928.85 million, a price-to-earnings ratio of -15.08 and a beta of 1.63. The firm has a 50 day moving average price of $9.47 and a 200-day moving average price of $5.26. Poseida Therapeutics, Inc. has a twelve month low of $1.87 and a twelve month high of $9.67. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.68.

Poseida Therapeutics (NASDAQ:PSTX) last posted its earnings results on Thursday, November 7th. The company reported $0.21 EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.63. The business had revenue of $71.75 million during the quarter, compared to the consensus estimate of $15.00 million. Poseida Therapeutics had a negative net margin of 40.28% and a negative return on equity of 72.26%. Equities research analysts forecast that Poseida Therapeutics, Inc. will post -1.02 earnings per share for the current year.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.